Research Progress, Benefit Groups, Treatment Cycle and Efficacy Prediction
of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.101.01
- Author:
Jingbin JI
1
;
Chenyu ZHANG
1
;
Lei PENG
1
;
Wenjie JIAO
1
Author Information
1. Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao 266071, China.
- Publication Type:Review
- Keywords:
Immune checkpoint inhibitors;
Immunotherapy;
Lung neoplasms;
Neoadjuvant therapy;
Perioperative;
Review
- MeSH:
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Humans;
Immune Checkpoint Inhibitors;
Immunotherapy/methods*;
Lung Neoplasms/drug therapy*;
Neoadjuvant Therapy
- From:
Chinese Journal of Lung Cancer
2022;25(2):92-101
- CountryChina
- Language:Chinese
-
Abstract:
The emergence of immune checkpoint inhibitors (ICIs) has dramatically changed the therapeutic outlook for patients with non-small cell lung cancer (NSCLC). Preoperative neoadjuvant immunotherapy has been paid more and more attention as an effective and safe treatment. Neoadjuvant immune therapy, however, the relevant research started late, relatively few research results and mainly focused on the small sample size of phase I and II studies, treatment itself exists many places it is not clear, also in benefit population screening, the respect such as the choice of treatment and curative effect prediction has not yet reached broad consensus. This paper reviews the important studies and recent achievements related to neoadjuvant immunotherapy, aiming to comprehensively discuss the procedures and existing problems of this kind of therapy from three aspects of beneficiary groups, treatment cycle and efficacy prediction.
.
